Management of hypertension and stroke prevention: Results of the Italian cardiologist survey

International Journal of Clinical Practice

Volumn 63, Issue 2, 2009, Pages 207-216

  Tocci, G ^a   Giovannelli, F ^a   Sciarretta, S ^a   Ferrucci, A ^a   Zito, G B ^b   Volpe, M ^a,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Associazioni Regionali Cardiologi Ambulatoriali   (Italy)

^c IRCCS NEUROMED   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ANTIHYPERTENSIVE AGENT;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOLOGIST; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; OUTPATIENT CARE; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; QUESTIONNAIRE; RISK FACTOR; STROKE; AMBULATORY CARE; BLOOD PRESSURE; CARDIOLOGY; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; HEALTH SURVEY; ITALY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PROFESSIONAL PRACTICE; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

AMBULATORY CARE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOLOGY; CARDIOVASCULAR DISEASES; HEALTH SURVEYS; HUMANS; HYPERTENSION; ITALY; PRIMARY PREVENTION; PROFESSIONAL PRACTICE; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 58449133087     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01926.x     Document Type: Article

References (48)

1. Olesen J, Leonardi M. The burden of brain diseases in Europe. Eur J Neurol 2003 10 : 471 7.
2. Lim SS, Gaziano TA, Gakidou E et al. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet 2007 370 : 2054 62.
3. Wolf-Maier K, Copper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003 289 : 2363 9.
4. Boersma E, Keil U, De Bacquer D et al. for the EUROASPIRE I and II Study Groups. Blood pressure is insufficiently controlled in European patients with established coronary heart disease. J Hypertens 2003 21 : 1831 40.
5. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990 335 : 765 74.
6. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990 335 : 827 39.
7. Kjeldsen SE, Julius S, Hedner T et al. Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials. Blood Press 2001 10 : 190 2.
8. Lewington S, Clarke R, Qizilbash N et al. for the Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 360 : 1903 13.
9. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial (MRFIT) research group. Arch Intern Med 1992 152 : 56 64.
10. Wannamethee SG, Shaper AG, Lennon L et al. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005 165 : 2644 50.
11. Di Tullio MR, Zwas DR, Sacco RL et al. Left ventricular mass and geometry and the risk of ischemic stroke. Stroke 2003 34 : 2380 4.
12. Kjeldsen SE, Fossum E, Reims HK et al. Hypertension treatment and stroke prevention. Blood Press 2003 12 : 264 8.
13. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003 362 : 1527 45.
14. Kjeldsen SE, Julius S. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am Heart J 2004 148 : 747 54.
15. Verdecchia P, Reboldi G, Angeli F et al. Angiotensin converting enzyme inhibitors and calcium channel blockers for coronary artery disease and stroke prevention. Hypertension 2005 46 : 386 92.
16. Vasan RS, Larson MG, Leip EP et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001 345 : 1291 7.
17. Liu L, Zhang Y, Guozhang L, Wei L et al. for the FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a Chinese randomised long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005 23 : 2157 73.
18. Andersson OK, Almgren T, Persson B et al. Survival in treated hypertension: follow up study after two decades. BMJ 1998 317 : 167 71.
19. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000 13 : 3S 10S.
20. Mancia G, Sega R, Milesi C et al. Blood-pressure control in the hypertensive population. Lancet 1997 349 : 454 7.
21. Volpe M, Tocci G, Trimarco B et al. Blood pressure control in Italy: results of recent surveys on hypertension. J Hypertens 2007 25 : 1491 8.
22. Volpe M, Tocci G. Antihypertensive therapy and cerebrovascular protection. Curr Opin Nephrol Hypertens 2006 15 : 498 504.
23. Bikkina M, Levy D, Evans JC et al. Left ventricular mass and risk of stroke in an elderly cohort. The Framingham Heart Study. JAMA 1994 272 : 33 6.
24. Lin HJ, Wolf PA, Kelly-Hayes M et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996 27 : 1760 4.
25. Foster MC, Hwang SJ, Larson MG et al. Cross-classification of microalbuminuria and reduced glomerular filtration rate: associations between cardiovascular disease risk factors and clinical outcomes. Arch Intern Med 2007 167 : 1386 92.
26. MacMahon S. The effects of antihypertensive drug treatment on the incidence of stroke and of coronary heart disease. Clin Exp Hypertens 1989 11 : 807 23.
27. Volpe M, Machado E. Treatment priorities and current prescribing patterns in hypertension: results of Global Research on Attitudes about hypertension and Stroke Prevention (GRASP), an international physician survey. Curr Med Res Opin 2004 20 : 1151 60.
28. Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med 2000 160 : 2281 6.
29. Oliveria SA, Lapuerta P, McCarthy BD et al. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002 162 : 413 20.
30. Cuspidi C, Michev I, Meani S et al. on behalf of the Lombardy Regional Section of the Italian Society of Hypertension. Awareness of hypertension guidelines in primary care: results of a regionwide survey in Italy. J Hum Hypertens 2003 17 : 451 7.
31. No authors listed. World Health Organization (WHO)/International Society of Hypertension (ISH) guidelines for the management of hypertension. J Hypertens 1999 17 : 151 83.
32. Mancia G, De Backer G, Dominiczak A et al. for the European Society of Cardiology. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 25 : 1105 87.
33. Volpe M, Erhardt LR, Williams B. Managing cardiovascular risk: the need for change. J Hum Hypertens 2008 22 : 154 7.
34. Haslam DW, James WPT. Obesity. Lancet 2005 366 : 1197 209.
35. Wachtell K, Olsen MH, Dahlof B et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J Hypertension 2002 20 : 405 12.
36. Bohm M, Thoenes M, Danchin N et al. Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study. J Hypertens 2007 25 : 2317 24.
37. Volpe M. Microalbuminuria screening in patients with hypertension: recommendations for clinical practice. Int J Clin Pract 2008 62 : 97 108.
38. Yusuf S, Sleight P, Dagenais G et al. for the Hearth Outcomes Prevention Evaluation (HOPE) Study Group. Effects of angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New Engl J Med 2000 342 : 145 53.
39. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 358 : 1033 41.
40. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002 288 : 2981 97.
41. Wing L, Reid C, Ryan P et al. for the Second Australian National Blood Pressure Study Group (ANBP2). A comparison of outcomes with angiotensin- converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003 348 : 583 92.
42. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the CAptopril Prevention Project (CAPPP) randomised trial. Lancet 1999 353 : 611 6.
43. Hansson L, Lindholm LH, Ekbom T et al. Randomised trial of old and new antihypertensive drugs on cardiovascular mortality and morbidity in elderly patients with hypertension: the Swedish Trial in Old Patients with Hypertension-2 (STOP-2). Lancet 1999 354 : 1751 6.
44. Dahlof B, Sever PS, Poulter NR et al. for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 366 : 895 906.
45. Dahlof B, Devereux RB, Kjeldsen SE et al., for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension (LIFE) study: a randomised trial against atenolol. Lancet 2002 359 : 995 1003.
46. Schrader J, Luders S, Kulschewski A et al. for the MOrbidity and Mortality after Stroke, Eprosartan compared with nitrendipine for Secondary prevention (MOSES) Study Group. Principal results of a prospective randomized controlled study. Stroke 2005 36 : 1218 26.
47. Reboldi G, Angeli F, Cavallini C et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens 2008 26 : 1282 9.
48. Margolis KL, Rolnick SJ, Fortman KK et al. Self-reported hypertension treatment beliefs and practices of primary care physicians in a managed care organization. Am J Hypertens 2005 18 : 566 71.